Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic
option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in …

Polymyxins have re-emerged in clinical practice owing to the dry antibiotic development
pipeline and worldwide increasing prevalence of nosocomial infections caused by multidrug …

Polymyxin B is increasingly used clinically for the treatment of multidrug-resistant Gram-
negative infections, despite very limited understanding of its disposition in humans. The …

Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative
bacterial infections. The objectives of this study were to examine the population …

Over the last several decades, bacterial resistance generated through the misuse of
antibiotics has been overcome by the development of new, safe, and effective antibiotics …

Administering polymyxin antibiotics in a traditional fashion may be ineffective against Gram-
negative ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae …

Background The pharmacokinetic/pharmacodynamic (PK/PD) relationship for polymyxin B
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …

Background: There has been a renewed interest in using polymyxin B as a last resort
therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite …

ABSTRACT A retrospective study was conducted in hospitalized patients receiving
intravenous polymyxin B who underwent therapeutic drug monitoring during treatment. The …

Antimicrobial resistance is increasing and few new antibiotics are in the development
pipeline. Alternative strategies to treat infectious diseases, such as combination therapy, are …